Rating: Sell — Conviction: Medium
An excellent business at a price that needs the AI-packaging capex cycle to run further and longer than any case I can honestly build. Revenue is inflecting hard — Q2 2026 up 35% year over year, backlog above $1bn for the first time — but the market capitalizes a non-GAAP stream that excludes ~$80mm a year of recurring merger and restructuring charges, and looks past how slowly growth converts to cash: working capital absorbs about 40 cents of every incremental revenue dollar. Discounted at a 5% risk-free rate, even a bull case with 25% multi-year growth and mid-30s EBITDA margins lands ~30% below the price.
Business overview
Onto sells inspection, metrology and lithography systems plus process-control software to chipmakers; it was formed by the 2019 Rudolph–Nanometrics merger. Demand splits into Advanced Nodes, Specialty Devices and Advanced Packaging, and software/services. In Q2 2026 Advanced Nodes revenue grew 50% sequentially to a record, and Specialty Devices and Advanced Packaging hit historic highs on 2.5D logic, HBM and silicon photonics. Three variables drive earnings: process-control intensity at advanced nodes and in packaging, systems-versus-software mix, and the working-capital cost of scaling a long-lead-time systems business. In August 2026 Onto paid ~$720mm for 27% of Japan's Rigaku Holdings from a $1.3bn+ 0.00% convertible; the stake is fair-valued, not consolidated.
Bull case
- AI packaging and HBM intensity — each layer of 2.5D/3D stacking adds metrology steps, so revenue outgrows wafer starts. Plays out if accelerator-driven HBM and packaging capacity additions run through 2027; backlog above $1bn already reaches into 2027. Model: rev_growth
- Advanced Nodes share gain — the 50% sequential jump was broad-based across logic and memory, which reads as design-win conversion, not one customer's pull-in. Plays out if Q3/Q4 hold the run-rate. Model: rev_growth
- Leverage as charges roll off — management targets non-GAAP operating margin of at least 33% by year-end against 30.0% in Q2, and the $4.3mm/quarter of merger expense is transitory. Plays out if restructuring decays with it. Model: ebitda_margin
- Rigaku broadens the served market — X-ray addresses the exotic materials and buried 3D structures optical metrology struggles with. A years 3–5 effect. Model: rev_growth
Bear case
- Working capital eats the growth — receivables plus inventory less payables have run 45.7%–61.8% of revenue since FY2021, $577mm in June. FY2026 consumes ~$140mm of cash in working capital alone, so free cash flow lags the margin story in exactly the years the multiple assumes cash. Model: nwc_pct_rev
- The price capitalizes non-GAAP earnings — the 25.6x forward P/E rests on EPS adding back $19.6mm a quarter of merger and restructuring charges. Onto creditably does not exclude share-based compensation ($17.0mm in H1), so the add-backs are operating charges. On GAAP-inclusive EBITDA the stock is at 40.5x trailing. Model: ebitda_margin
- Air pocket after a pull-forward — semicap revenue mean-reverts: FY2022's $1,005mm fell 19% to $816mm in FY2023. A 42% year is usually followed by digestion; bear assumes one down year in FY2027. Model: rev_growth
- Duration risk at a 5% risk-free rate — beta 1.58 at 11x sales, 10Y at 5.00%, 16 of 18 FOMC participants expecting another hike. Why S3 and S12 dominate the stress test. Model: wacc, exit_ev_ebitda
Valuation & balance sheet
| Metric (definition) | Current | Own history (range or 5y avg) | Peers | Source, as-of |
|---|---|---|---|---|
| Forward P/E (consensus non-GAAP EPS, NTM) | 25.6x | n/a (unverified) | KLA 33.8x · Camtek 35.6x | stockanalysis statistics / GuruFocus, 2026-09-21 |
| EV/EBITDA (TTM, EV $12.52bn) | 40.5x | n/a (unverified) | KLA ~42.9x · Nova ~36.6x · Camtek ~30.4x | stockanalysis statistics / GuruFocus, 2026-09-21 |
| EV/Sales (TTM revenue $1.12bn) | 11.2x | n/a (unverified) | n/a (unverified) | stockanalysis statistics, 2026-09-21 |
| EBITDA margin (GAAP op. income + D&A / revenue) | 19.2% FY2025 · 23.2% H1 2026 | 19.2%–30.0%, 5y avg 25.0% | n/a (unverified) | SEC EDGAR XBRL + Q2 2026 release, 2026-09-21 |
| FCF yield (TTM FCF $252.5mm / mkt cap) | 2.0% | n/a (unverified) | n/a (unverified) | stockanalysis statistics, 2026-09-21 |
Model-implied value range (from model-summary.json; generic module, DCF-Gordon and DCF-exit-multiple, midpoints): Bear $41.77 · Base $104.13 · Bull $185.44 per share, i.e. implied returns of −84.1% / −60.5% / −29.6% vs $263.43. These ranges show how the bull and bear drivers translate into value; they are not price targets. The price sits above the bull case: $263 needs the bull revenue and margin path and a 9% WACC and a 22x exit together.
Rigaku is excluded from every case. The stake is deducted from cash at its ~$720mm cost and never added back, because the generic module has no line for a fair-value holding. That understates all three cases by ~$14.50 per share at cost, and does not change the direction of the call.
Balance sheet: net leverage 1.60x FY0 EBITDA (0.8x on base FY2026E); coverage not meaningful — the only borrowing is a 0.00%-coupon convertible, modeled EBITDA/net interest 240x in Y1. Liquidity $1,162mm of cash and securities pro forma for Rigaku against $1,471.7mm of notes, the whole stack maturing at once on 2031-06-01. No agency rating retrieved this session.
Model note: built and LibreOffice-verified (3,188 formula cells matched, 0 failing error checks). One warning check fails: market.cash is unverified, derived as the 2026-06-30 balance of $1,882.2mm less the ~$720mm Rigaku payment. No assumptions lack a basis; no scenario CHECKs remain. Two judgment inputs are weaker than the rest and say so in their basis: capex at 3% of revenue, and the 15% cash tax rate inferred from Q2. Cost-of-debt is charged on net debt only, ignoring ~$45mm a year of interest income on gross cash. Generator note (2026-09-24): in this module share_change, capital_return_pct and cost_of_debt move EPS and the net-cash path only, and peer_pe feeds a cross-check only; none changes the value range, so bull/bear tags no longer cite them. Scenario deltas were rebuilt after multiple_pct shocks were extended to the Gordon method (previously they moved only the exit-multiple half), and EPS now uses average diluted shares.
Scenario stress test
Reasoned from the bull/bear drivers above. The model column comes from the scenario overlays (Base case + shock).
| Scenario | Effect | Mechanism | Magnitude | Model Δ value vs Base ($/sh) |
|---|---|---|---|---|
| S1 Fast equity crash | − | Beta 1.58 at 11x sales: multiple compresses on de-risking, backlog untouched | High | −$24.91 |
| S2 Slow bear / recession | − | Customers defer deliveries; backlog stretches instead of shipping, underutilization hits margin | High | −$37.32 |
| S3 Rapid rate shock | − | Long-duration equity de-rates on the yield spike; no floating debt, so no interest-cost channel | High | −$26.40 |
| S4 Slow rate grind | − | Same channel, slower and shallower, across the full horizon | Med | −$17.20 |
| S5 Soft-landing cuts | + | Cheaper money plus intact fab investment is the best regime for a high-multiple equipment name | High | +$21.50 |
| S6 Recession-driven cuts | − | Capex cuts dominate the discount-rate relief | High | −$21.45 |
| S7a Credit liquidity shock | − | Mostly a multiple event: no maturity before 2031, no revolver to roll | Low | −$13.99 |
| S7b Slow default cycle | − | Large chipmakers are investment grade, but levered OSAT and specialty buyers slow orders | Low | −$7.13 |
| S8 Stagflation | − | Input and labor inflation squeeze margin faster than system pricing resets; discount rate rises | Med | −$20.18 |
| S9a Dollar spike | − | Asia-concentrated revenue translates lower; the yen-denominated Rigaku stake marks down | Low | −$4.66 |
| S9b Dollar slide | + | Mirror image: translation tailwind plus a yen-asset gain | Low | +$3.96 |
| S10 Melt-up | + | Rewards exactly this profile: high beta, AI-levered, narrow leadership | High | +$27.13 |
| S11 Energy supply shock | − | Freight and energy input costs on globally shipped systems; no direct demand channel | Low | −$4.60 |
| S12 Mega-cap/AI derating | − | The re-rating rests on AI packaging and HBM intensity; a leadership unwind takes multiple and orders both | High | −$35.64 |
Magnitude labels re-ranked 2026-09-25 to match the model's dollar deltas (skill 3a-v-b item 7; the 2026-09-24 generator fix enlarged multiple-shock rows): S5 Med→High.
Currently active/on watch per the playbook: S3 partially active (10Y 5.00%, price leg met, pace legs short); S8, S10, S11 on watch, S11 escalated after the 2026-09-19/20 Houthi strikes on Riyadh and Yanbu.
What would change the call
Upgrades if: the bull operating profile shows up — revenue above a $1.6bn annualized run-rate, GAAP-inclusive EBITDA margin above 30%, working capital below 38% of revenue — while the price de-rates into the $185–235 bull range; or a sustained fall in the 10Y resets the discount rate the whole group is capitalized at. Downgrades if: conviction goes to High rather than the rating changing — backlog below $1bn, restructuring above $15mm a quarter into FY2027, or the GAAP-to-non-GAAP gap widening on new charges.
Watch items
- W1: "Restructuring expenses and other" ($15.3mm Q2, $30.7mm H1) — below $8mm/quarter, and any disclosure of what it is — Q3 non-GAAP reconciliation and 10-Q — late Oct/early Nov 2026 — Model: ebitda_margin
- W2: Working-capital intensity (AR + inventory − AP over annualized revenue, 42% in Q2) — under 38% supports bull, over 46% confirms bear:1 — quarterly balance sheet — Model: nwc_pct_rev
- W3: Backlog, above $1bn and reaching into 2027 — holds and extends, or erodes — Q3 earnings release and call — Model: rev_growth
- W4: Amortization, $19.7mm in Q2 against $39.4mm for all of FY2025 — what drove the step-up, and does ~$79mm annualized persist — intangibles note, Q3 10-Q — Model: da_pct_rev
Sources
- Onto Innovation Reports 2026 Second Quarter Results (2026-08-06), incl. GAAP/non-GAAP reconciliation and balance sheet — https://investors.ontoinnovation.com/news/news-details/2026/Onto-Innovation-Reports-2026-Second-Quarter-Results/default.aspx — accessed 2026-09-21
- Onto Innovation Form 10-Q, quarter ended 2026-06-30 — https://www.sec.gov/Archives/edgar/data/704532/000119312526338401/onto-20260630.htm — accessed 2026-09-21
- SEC EDGAR XBRL companyconcept, CIK 0000704532: RevenueFromContractWithCustomerExcludingAssessedTax, OperatingIncomeLoss, Depreciation, AmortizationOfIntangibleAssets, AccountsReceivableNetCurrent, InventoryNet, AccountsPayableCurrent — https://data.sec.gov/api/xbrl/companyconcept/CIK0000704532/us-gaap/RevenueFromContractWithCustomerExcludingAssessedTax.json — accessed 2026-09-21
- Onto Innovation Finalizes Strategic Stake in Rigaku Holdings, Form 8-K exhibit 99.1 (2026-08-10) — https://www.sec.gov/Archives/edgar/data/0000704532/000119312526341337/d125405dex991.htm — accessed 2026-09-21
- Onto Innovation Announces Pricing of Upsized Private Offering of $1.3 Billion of 0.00% Convertible Senior Notes Due 2031 (2026-05-19) — https://investors.ontoinnovation.com/news/news-details/2026/Onto-Innovation-Announces-Pricing-of-Upsized-Private-Offering-of-1-3-Billion-of-0-00-Convertible-Senior-Notes-Due-2031/default.aspx — accessed 2026-09-21
- Onto Innovation quote and statistics pages — https://stockanalysis.com/stocks/onto/ and https://stockanalysis.com/stocks/onto/statistics/ — accessed 2026-09-21
- Peer forward P/E (KLA 33.79x, Camtek 35.55x) — https://www.gurufocus.com/term/forward-pe-ratio/KLAC and https://www.gurufocus.com/term/forward-pe-ratio/CAMT — accessed 2026-09-21
- Portfolio command center macro log, 2026-09-18 entry (10Y 5.00%, S&P 7,650.50, VIX 14.81) — logs/macro-2026-09.md — accessed 2026-09-21